Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,815 across all filing types
Latest filing 2025-06-10 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2025-06-10 English
Transaction in Own Shares 2025
Transaction in Own Shares Classification · 1% confidence The document consists entirely of tables detailing transactions (Issuer, Date, Time, Quantity, Price, Venue) for the issuer GENMAB A/S on the XCSE exchange over several days in June 2025. This structure is characteristic of regulatory filings reporting insider transactions or significant share dealings by directors/executives. Comparing this content to the definitions, it most closely matches 'Director's Dealing' (DIRS), which covers personal share transactions by directors and executives. Although the text doesn't explicitly state 'Director's Dealing', the format strongly suggests a record of insider trading activity.
2025-06-10 English
Transaction in Own Shares 2025
Transaction in Own Shares Classification · 1% confidence The document is explicitly titled "Transactions in Connection with Share Buy-back Program" and details the number of shares repurchased, the average price, and the total value executed between specific dates (June 2 to June 6, 2025) under an existing program announced on March 25, 2025. This content directly relates to the company managing its own stock, which aligns perfectly with the definition for 'Transaction in Own Shares' (POS). It is not a general regulatory filing (RNS) because it is highly specific, nor is it a general capital change announcement (SHA), as it focuses solely on repurchases/buy-backs.
2025-06-10 English
Transaction in Own Shares 2025
Transaction in Own Shares Classification · 1% confidence The document is titled "Transactions in Connection with Share Buy-back Program" and details the execution of share repurchases between June 2 and June 6, 2025. This activity directly relates to the company managing its own shares, which aligns precisely with the definition of 'Transaction in Own Shares'. The document is a company announcement detailing these specific transactions, not a general regulatory filing (RNS) or an announcement about a different report. Therefore, the appropriate code is POS.
2025-06-10 English
6-K
Foreign Filer Report
2025-06-02 English
Transactions in Connection with Share Buy-back Program
Transaction in Own Shares Classification · 1% confidence The document provides a detailed, transaction-by-transaction log of share buyback activities (date, time, quantity, price, and venue) for Genmab A/S. This is a standard disclosure for a company executing a share repurchase program, which falls directly under the 'Transaction in Own Shares' category.
2025-06-02 Danish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.